NEW_CURA-LEAF_1170x120_OCT

Meda

Mylan closes acquisition of Meda

Mylan closes acquisition of Meda

PITTSBURGH — Mylan N.V. has completed its $9.9 billion deal to acquire Sweden-based Meda AB. Mylan had received Federal Trade Commission clearance for the transaction in late July. The deal was announced in February. The combination of Mylan and Meda creates a leading pharmaceutical company with a strong portfolio of brand-name and generic drugs and

FTC clears Teva-Allergan, Mylan-Meda acquisitions

FTC clears Teva-Allergan, Mylan-Meda acquisitions

NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied

Mylan to acquire Meda in $9.9 billion deal

Mylan to acquire Meda in $9.9 billion deal

HERTFORDSHIRE, England — Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion. Executives from both companies noted that a Mylan-Meda combination would create